The Impact of Exacerbation Frequency on Clinical and Economic Outcomes in Swedish COPD Patients: The ARCTIC Study

被引:13
作者
Larsson, Kjell [1 ]
Janson, Christer [2 ]
Lisspers, Karin [3 ]
Stallberg, Bjorn [3 ]
Johansson, Gunnar [3 ]
Gutzwiller, Florian S. [4 ]
Mezzi, Karen [4 ]
Bjerregaard, Bine Kjoeller [5 ]
Jorgensen, Leif [5 ]
机构
[1] Karolinska Inst, Natl Inst Environm Med, Integrat Toxicol, SE-17177 Stockholm, Sweden
[2] Uppsala Univ, Dept Med Sci Resp Allergy & Sleep Res, Uppsala, Sweden
[3] Uppsala Univ, Dept Publ Hlth & Caring Sci, Family Med & Prevent Med, Uppsala, Sweden
[4] Novartis Pharma AG, Global Patient Access, Basel, Switzerland
[5] IQVIA Solut, Real World Evidence Solut, Copenhagen, Denmark
关键词
chronic obstructive pulmonary disease; exacerbations; mortality; lung function; healthcare cost; Sweden; OBSTRUCTIVE PULMONARY-DISEASE; MANAGEMENT; DIAGNOSIS; MORTALITY; OVERLAP; DECLINE;
D O I
10.2147/COPD.S297943
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Purpose: The aim of this study was to assess the association between exacerbation frequency and clinical and economic outcomes in patients with COPD. Patients and Methods: Electronic medical record data linked to National Health Registries were collected from COPD patients at 52 Swedish primary care centers (2000-2014). The outcomes analyzed were exacerbation rate, mortality, COPD treatments, lung function and healthcare costs during the follow-up period. Based on the exacerbation rate two years before index date, the patients were initially classified into three groups, either 0, 1 or >= 2 exacerbations per year. After the index date, the classification into exacerbation groups was updated each year based on the exacerbation rate during the last year of follow-up. A sensitivity analysis was conducted excluding patients with asthma diagnosis from the analysis. Results: In total 18,586 COPD patients were analyzed. A majority of the patients (60-70%) who either have had no exacerbation or frequent exacerbations (>= 2/year) during the preindex period remained in their group (ie, with 0 or >= 2 annual exacerbations) during up to 11 years of follow-up. Compared with having no exacerbation, mortality was higher in patients having 1 (HR; 2.06 [1.93-2.201) and >= 2 (4.58 [4.33-4.841) exacerbations at any time during the follow-up. Lung function decline was more rapid in patients with frequent exacerbations and there was an almost linear relationship between exacerbations frequency and mortality. Total healthcare costs were higher in the frequent exacerbation group (>= 2/year) than in patients with no or one exacerbation annually (p<0.0001 for both). The results did not differ from the main analysis after exclusion of patients with a concurrent asthma diagnosis. Conclusion: In addition to faster lung function decline and increased mortality, frequent exacerbations in COPD patients imply a significant economic burden.
引用
收藏
页码:701 / 713
页数:13
相关论文
共 25 条
[1]   Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials [J].
Bafadhel, Mona ;
Peterson, Stefan ;
De Blas, Miguel A. ;
Calverley, Peter M. ;
Rennard, Stephen I. ;
Richter, Kai ;
Fageras, Malin .
LANCET RESPIRATORY MEDICINE, 2018, 6 (02) :117-126
[2]   The Clinical and Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease: A Cohort of Hospitalized Patients [J].
Blasi, Francesco ;
Cesana, Giancarlo ;
Conti, Sara ;
Chiodini, Virginio ;
Aliberti, Stefano ;
Fornari, Carla ;
Mantovani, Lorenzo Giovanni .
PLOS ONE, 2014, 9 (06)
[3]   Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper [J].
Celli, BR ;
MacNee, W ;
Agusti, A ;
Anzueto, A ;
Berg, B ;
Buist, AS ;
Calverley, PMA ;
Chavannes, N ;
Dillard, T ;
Fahy, B ;
Fein, A ;
Heffner, J ;
Lareau, S ;
Meek, P ;
Martinez, F ;
McNicholas, W ;
Muris, J ;
Austegard, E ;
Pauwels, R ;
Rennard, S ;
Rossi, A ;
Siafakas, N ;
Tiep, B ;
Vestbo, J ;
Wouters, E ;
ZuWallack, R .
EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (06) :932-946
[4]  
Dal Negro Roberto, 2008, Int J Chron Obstruct Pulmon Dis, V3, P1
[5]   Impact of COPD Exacerbation Frequency on Costs for a Managed Care Population [J].
Dalal, Anand A. ;
Patel, Jeetvan ;
D'Souza, Anna ;
Farrelly, Eileen ;
Nagar, Saurabh ;
Shah, Manan .
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2015, 21 (07) :575-U108
[6]  
Dalal Anand A, 2010, Int J Chron Obstruct Pulmon Dis, V5, P341, DOI 10.2147/COPD.S13771
[7]   Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease [J].
Donaldson, GC ;
Seemungal, TAR ;
Bhowmik, A ;
Wedzicha, JA .
THORAX, 2002, 57 (10) :847-852
[8]   NATURAL-HISTORY OF CHRONIC AIR-FLOW OBSTRUCTION [J].
FLETCHER, C ;
PETO, R .
BMJ-BRITISH MEDICAL JOURNAL, 1977, 1 (6077) :1645-1648
[9]   Asthma-COPD overlap 2015: now we are six [J].
Gibson, Peter G. ;
McDonald, Vanessa M. .
THORAX, 2015, 70 (07) :683-691
[10]  
Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2020, Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, DOI DOI 10.1183/13993003.00427-2018